Skip to main content
padlock icon - secure page this page is secure

Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines

Buy Article:

$59.00 + tax (Refund Policy)

Min C-K, Lee S, Kim Y-J, Eom K-S, Lee J-W, Min W-S, Kim C-C, Cho C-S, Park G. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.

Eur J Haematol 2006. © Blackwell Munksgaard 2006. Abstract: 

The proteasome inhibitor, bortezomib, has anti-myeloma activity even in myeloma cells refractory to multiple prior treatments. Bortezomib blocks the production of nuclear factor-B (NFB)-mediated pro-inflammatory cytokines. We report a patient with myeloma who developed a cutaneous leucoclastic vasculitis (LV) after bortezomib treatment. The patient with LV exhibited a marked increase in serum levels of IL-6, TNF-α, and C-reactive protein (CRP). Bortezomib administration may enhance the release of pro-inflammatory cytokines, which might play a role in bortezomib-induced cutaneous LV.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: IL-6; TNF-α; bortezomib; leucolcastic vasculitis; multiple myeloma

Document Type: Research Article

Affiliations: Department of Clinical Pathology, St. Mary's Hospital, Seoul, South Korea

Publication date: March 1, 2006

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more